Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply to S. Girnius et al.
Palladini G, Dispenzieri A, Gertz M, Kumar S, Wechalekar A, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. Palladini G, et al. Among authors: wechalekar a. J Clin Oncol. 2013 Jul 20;31(21):2750-1. doi: 10.1200/JCO.2013.49.2512. J Clin Oncol. 2013. PMID: 24040662 No abstract available.
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.
Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Comenzo RL, et al. Among authors: wechalekar a. Leukemia. 2012 Nov;26(11):2317-25. doi: 10.1038/leu.2012.100. Epub 2012 Apr 5. Leukemia. 2012. PMID: 22475872 Review.
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. Palladini G, et al. Among authors: wechalekar a. J Clin Oncol. 2012 Dec 20;30(36):4541-9. doi: 10.1200/JCO.2011.37.7614. Epub 2012 Oct 22. J Clin Oncol. 2012. PMID: 23091105
Immunoglobulin light chain amyloidosis.
Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA. Merlini G, et al. Among authors: wechalekar a. Expert Rev Hematol. 2014 Feb;7(1):143-56. doi: 10.1586/17474086.2014.858594. Epub 2013 Dec 18. Expert Rev Hematol. 2014. PMID: 24350907 Review.
Update on treatment of light chain amyloidosis.
Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Mahmood S, et al. Among authors: wechalekar a. Haematologica. 2014 Feb;99(2):209-21. doi: 10.3324/haematol.2013.087619. Haematologica. 2014. PMID: 24497558 Free PMC article. Review.
Guidelines on the diagnosis and investigation of AL amyloidosis.
Gillmore JD, Wechalekar A, Bird J, Cavenagh J, Hawkins S, Kazmi M, Lachmann HJ, Hawkins PN, Pratt G; BCSH Committee. Gillmore JD, et al. Among authors: wechalekar a. Br J Haematol. 2015 Jan;168(2):207-18. doi: 10.1111/bjh.13156. Epub 2014 Oct 14. Br J Haematol. 2015. PMID: 25312307 Free article. No abstract available.
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.
Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, Maurer MS, Sanchorawala V, Wechalekar A, Palladini G, Comenzo RL. Merlini G, et al. Among authors: wechalekar a. Leukemia. 2016 Oct;30(10):1979-1986. doi: 10.1038/leu.2016.191. Epub 2016 Jul 15. Leukemia. 2016. PMID: 27416985 Free PMC article. Review.
259 results